Wellington Management Group LLP Sells 32,486 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Wellington Management Group LLP lowered its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 454,649 shares of the company’s stock after selling 32,486 shares during the quarter. Wellington Management Group LLP owned about 0.98% of Pacira BioSciences worth $6,842,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in PCRX. Outfitter Financial LLC increased its holdings in shares of Pacira BioSciences by 5.7% in the second quarter. Outfitter Financial LLC now owns 20,190 shares of the company’s stock valued at $578,000 after purchasing an additional 1,095 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Pacira BioSciences by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company’s stock valued at $685,000 after buying an additional 1,354 shares during the period. nVerses Capital LLC raised its position in shares of Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after acquiring an additional 1,600 shares during the last quarter. Innealta Capital LLC acquired a new position in shares of Pacira BioSciences during the second quarter valued at $50,000. Finally, Bank of New York Mellon Corp boosted its holdings in Pacira BioSciences by 0.5% in the second quarter. Bank of New York Mellon Corp now owns 400,002 shares of the company’s stock valued at $11,444,000 after acquiring an additional 2,141 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

NASDAQ PCRX opened at $19.87 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market cap of $917.46 million, a price-to-earnings ratio of -9.79 and a beta of 0.80. The business has a 50 day simple moving average of $17.27 and a 200 day simple moving average of $18.97. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $35.95.

Analyst Upgrades and Downgrades

PCRX has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Royal Bank of Canada lifted their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Jefferies Financial Group increased their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Barclays decreased their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a research note on Friday, November 8th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.